目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T81272 | |||
RIOK2-IN-1 (com 4) 是一种高选择性 RIOK2 抑制剂,Kd 值为 150 nM,但其细胞活性相对低下,IC50 值达 14,600 nM。RIOK2 作为一种非典型激酶,在多种人类癌症中扮演角色,涉及核糖体成熟和细胞周期的进展。基于 RIOK2-IN-1,开发出的新型小分子抑制剂 CQ211 显示出突出的体内外活性,能有效抑制 MKN-1 和 HT-29 癌细胞增殖,并在小鼠异种移植的 MKN-1 模型中抑制了肿瘤的发展。 | |||
T83667 | |||
A11是一种细胞穿透肽,由HIV-1 Tat蛋白质转导域与对应于脂联素A1 N末端第20至30残基的11氨基酸肽连接而成。它减少脂联素A1与Eph受体酪氨酸激酶A2(EphA2)的结合,并在HK1鼻咽癌(NPC)细胞中增加EphA2的泛素化。A11(10 µM)抑制HK1和5-8F NPC细胞的增殖、迁移和侵袭。在体内,A11减少5-8F和HK1 NPC小鼠异种移植模型中的肿瘤体积。 | |||
T79487 | Monoamine Oxidase | ||
MAO A/HSP90-IN-2(compound 4-C)是一种针对HSP90和MAO A的双重抑制剂,显示出分别对这两种酶有0.016 μM和4.58 μM的IC50值。该化合物能够上调HSP70,降低HER2和磷酸化AKT的表达,同时能减少GL26细胞中由IFN-γ诱导的PD-L1表达增加。此外,MAO A/HSP90-IN-2能够抑制对Temozolomide敏感或耐药的胶质母细胞瘤(GBM)、结肠癌、白血病和非小细胞肺癌细胞的生长,并可能有助于阻止肿瘤逃避免疫监控。 | |||
T78810 | Androgen Receptor | ||
BWA-522是一种口服有效的小分子PROTACs,针对AR-FL和AR-V7显示出显著的降解活性。该化合物通过对Androgen Receptor的AR-NTD进行拮抗,诱发PC细胞的apoptosis。在LNCaP异种移植模型中,BWA-522以每日60 mg/kg的剂量口服给药,实现了76%的肿瘤生长抑制(TGI=76%)。在VCaP和LNCaP细胞系中对AR-V7和AR-FL的降解效率分别达到77.3%(1 μM)和72.0%(5 μM)。 | |||
T36057 | |||
Diallyl tetrasulfide is an organosulfur compound that has been found in A. sativum and has diverse biological activities, including antimicrobial, antioxidant, and anticancer properties.[1],[2],[3],[4] It is active against the bacteria S. aureus and methicillin-resistant S. aureus (MRSA; MICs = 0.5 and 2 mg/L, respectively), as well as the fungi C. albicans, C. krusei, C. glabrata, A. niger, A. flavus, and A. fumigatus (MICs = 0.5, 4, 2, 1, 2, and 4 mg/L, respectively).[1] It reduces cadmium-induced increases in hepatic levels of thiobarbituric acid reactive substances (TBARS) and increases cadmium-induced decreases in the hepatic activity of superoxide dismutase (SOD1), catalase, GST, and glucose-6-phosphate dehydrogenase (G6PDH) in rats when administered at a dose of 40 mg/kg.[2] Diallyl tetrasulfide is cytotoxic to MCF-7 breast cancer cells (IC50 = 92 μM) and reduces tumor growth in a BGC-823 mouse xenograft model when administered at doses of 20, 30, and 40 mg/kg for 32 days.[3],[4] | |||
T35683 | |||
2-deoxy-D-Glucose-13C6is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.32-deoxy-D-Glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg/ml.4,5In vivo, 2-deoxy-D-glucose (500 mg/kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel .6 1.Kang, H.T., and Hwang, E.S.2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimeticLife Sci.78(12)1392-1399(2006) 2.Aft, R.L., Zhang, F.W., and Gius, D.Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell deathBr. J. Cancer87(7)805-812(2002) 3.Ralser, M., Wamelink, M.M., Struys, E.A., et al.A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growthProc. Natl. Acad. Sci. USA105(46)17807-17811(2008) 4.Liu, H., Savaraj, N., Priebe, W., et al.Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C)Biochem. Pharmacol.64(12)1745-1751(2002) 5.Zhang, X.D., Deslandes, E., Villedieu, M., et al.Effect of 2-deoxy-D-glucose on various malignant cell lines in vitroAnticancer Res.26(5A)3561-3566(2006) 6.Maschek, G., Savaraj, N., Priebe, W., et al.2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res.64(1)31-34(2004) | |||
TN2977 | Caspase Antifection | ||
3-O-(E)-p-coumaroyl tormentic acid may be promising lead compound for developing an effective drug for treatment of leukemia, it induces apoptotic cell death in human leukemia (HL60) via mainly mitochondrial pathway by, at least in part, Topo I inhibition. 3-O-trans-p-coumaroyltormentic acid shows cytotoxicity against four human tumor cell lines (A549, SK-OV-3, SK-MEL-2, and HCT-15) in vitro, the IC50 values of 13.72, 14.29,14.61, 14.04 uM, respectively. 3beta-O-cis-p-Coumaroyltormentic acid, and 3beta-O-trans-p-coumaroyltormentic acid are weakly selective for vancomycin-resistant Enterococcus (VRE) compared with eukaryotic cells, with an MIC of 59.4microg/mL and a 50% inhibitory concentration (IC50) of 72.0microg/mL for monkey kidney epithelial (MA104) cells. A mixture of 3-O-cis-p-coumaroyltormentic acid and 3-O-trans-p-coumaroyltormentic acid shows an inhibitory effect comparable to (-)-epigallocatechin gallate (EGCG) of green tea on the activation of Epstein-Barr virus early antigen (EBV-EA) induced by 12-O-tetradeca--noylphorbol-13-acetate (TPA). | |||
T35672 | |||
SMU127 is an agonist of the toll-like receptor 1/2 (TLR1/2) heterodimer.1It induces NF-κB signaling in cells expressing human TLR2 (EC50= 0.55 μM) but not cells expressing human TLR3, -4, -5, -7, or -8 when used at concentrations ranging from 0.1 to 100 μM. SMU127 induces the production of TNF-α in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 0.01 to 1 μM.In vivo, SMU127 (0.1 mg/animal) reduces tumor volume in a 4T1 murine mammary carcinoma model. 1.Chen, Z., Cen, X., Yang, J., et al.Structure-based discovery of a specific TLR1-TLR2 small molecule agonist from the ZINC drug library databaseChem. Commun. (Camb.)54(81)11411-11414(2018) | |||
T83871 | |||
Ferroptocide是一种抑制剂,可抑制硫氧还蛋白(Trx)活性,并且是pleuromutilin的衍生物。在20 µM的浓度下,Ferroptocide能够抑制ES-2卵巢癌细胞中的Trx活性,并对ES-2细胞具有细胞毒性(IC50 = 1.6 µM)。5 µM的Ferroptocide能够诱导ES-2细胞发生铁死亡,这一效应可以通过铁螯合剂去铁胺(DFO)、抗氧化剂Trolox或铁死亡抑制剂ferrostatin-1来阻断。在使用免疫完整但非免疫缺陷小鼠的4T1小鼠乳腺癌模型中,每周两次以50 mg/kg剂量给药时,Ferroptocide能够减少肿瘤体积。 | |||
T36701 | |||
Phosphoramide mustard cyclohexanamine is the major metabolite for Cyclophosphamide , with anticancer activitiy. Phosphoramide mustard cyclohexanamine induces DNA adduct formation in ovarian granulosa cells, induces DNA damage and elicits the ovarian DNA repair response[1][2]. Phosphoramide mustard cyclohexanamine causes cytotoxicity through forming cross-linked DNA adducts which inhibit DNA strand separation during replication[1].Phosphoramide mustard cyclohexanamine destroys rapidly dividing cells by forming NOR-G-OH, NOR-G and G-NOR-G adducts with DNA, potentially leading to DNA damage[1].Phosphoramide mustard cyclohexanamine (3-6 μM; 48 hours) reduces cell viability in rat spontaneously immortalized granulosa cells (SIGCs)[1].Phosphoramide mustard cyclohexanamine (3-6 μM; 24-48 hours) induces DNA adduct formation[1].Phosphoramide mustard cyclohexanamine (3-6 μM; 24-48 hours) induces ovarian DNA damage in rat ovaries[1].Phosphoramide mustard cyclohexanamine increases DNA damage responses (DDR) gene (Atm, Parp1, Prkdc, Xrcc6, Brca1, Rad51) mRNA expression level[1].Phosphoramide mustard cyclohexanamine (3-6 μM; 24-48 hours) increased DDR proteins[1]. Cell Viability Assay[1] Cell Line: SIGCs Phosphoramide mustard cyclohexanamine (2.1-20.7 mg/kg; i.p.; daily; for 5 days) inhibits subcutaneous tumor growth in rats[2].Phosphoramide mustard cyclohexanamine (86.0 mg/kg; i.v.) has a plasma disappearance half-life of 15.1 minutes[2]. Animal Model: Rat, subcutaneously implanted Walker 256 carcinosarcoma tumor[2] [1]. Shanthi Ganesan, et al. Phosphoramide mustard exposure induces DNA adduct formation and the DNA damage repair response in rat ovarian granulosa cells. Toxicol Appl Pharmacol. 2015 Feb 1; 282(3): 252-258. [2]. S Genka, et al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother Pharmacol. 1990;27(1):1-7. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-05153 | TROP-2 Protein, Cynomolgus, Rhesus, Recombinant (His) | Cynomolgus,Rhesus | HEK293 Cells | ||
TROP-2 Protein, Cynomolgus, Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 28.7 kDa and the accession number is XP_001114599.1.
|
|||||
TMPY-01429 | RELT/TNFRSF19L Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
RELT/TNFRSF19L Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 15.7 kDa and the accession number is A0A024R5N3.
|
|||||
TMPY-03645 | BAFF/TNFSF13B Protein, Cynomolgus, Recombinant (hFc) | Cynomolgus | HEK293 Cells | ||
BAFF/TNFSF13B Protein, Cynomolgus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 38.1 kDa and the accession number is F7H548.
|
|||||
TMPY-04289 | CD30L Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
CD30L Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 22 kDa and the accession number is G7P2F1.
|
|||||
TMPY-05504 | 4-1BB/CD137/TNFRSF9 Protein, Rhesus, Recombinant (His), Biotinylated | Rhesus | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Rhesus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 18.7 kDa and the accession number is XP_005544945.1&NP_001253057.1.
|
|||||
TMPY-03213 | BCMA/TNFRSF17 Protein, Rhesus, Recombinant (hFc) | Rhesus | HEK293 Cells | ||
BCMA/TNFRSF17 Protein, Rhesus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 33 kDa and the accession number is A0A2K5UD97.
|
|||||
TMPY-03101 | TNFR2/CD120b/TNFR1B Protein, Cynomolgus, Rhesus, Recombinant (His) | Cynomolgus,Rhesus | HEK293 Cells | ||
TNFR2/CD120b/TNFR1B Protein, Cynomolgus, Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.5 kDa and the accession number is XP_005544817.1&NP_001253134.1.
|
|||||
TMPY-02202 | TNF alpha Protein, Rat, Recombinant | Rat | E. coli | ||
TNF alpha Protein, Rat, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 17.4 kDa and the accession number is P16599.
|
|||||
TMPY-04146 | TNF alpha Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
TNF alpha Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 45.8 kDa and the accession number is P01375.
|
|||||
TMPJ-00779 | TNF alpha Protein, Rabbit, Recombinant | Rabbit | E. coli | ||
Tumor necrosis factor alpha (TNFα) is the prototypic ligand of the TNF superfamily. TNFα forms a homotrimer and functions by activating two types of receptors TNF-R1 (TNF receptor type 1,p55R) and TNF-R2 (TNF receptor type 2,p75R). TNFα is a pleiotropic cytokine that is capable to promote inflammation, to induce apoptotic cell death, and to inhibit tumorigenesis and viral replication. TNFα is a potent lymphoid factor that exerts cytotoxic effects on a wide range of tumor cells and certain other target cells.
|
|||||
TMPY-00705 | CD30L Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
CD30L Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 47.8 kDa and the accession number is P32971.
|
|||||
TMPJ-00139 | 4-1BB Ligand/TNFSF9 Protein, Human, Recombinant (His) | Human | E. coli | ||
4-1BB Ligand/TNFSF9 Protein, Human, Recombinant (His) is expressed in E. coli expression system with C-6xHis tag. The predicted molecular weight is 16-20 KDa and the accession number is P41273.
|
|||||
TMPY-04645 | TL1A/TNFSF15 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
TL1A Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 48.9 kDa and the accession number is A0A0U5JA19.
|
|||||
TMPY-05568 | BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated | Human | HEK293 Cells | ||
BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated is expressed in HEK293 mammalian cells with His and Fc tag. The accession number is NP_001183.2.
|
|||||
TMPY-05319 | BCMA/TNFRSF17 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
BCMA/TNFRSF17 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 7.3 kDa and the accession number is Q02223-1.
|
|||||
TMPY-01827 | CD30/TNFRSF8 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
CD30/TNFRSF8 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 40 kDa and the accession number is P28908-1.
|
|||||
TMPY-05594 | 4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc & Avi), Biotinylated | Human | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag. The predicted molecular weight is 45.8 kDa and the accession number is Q07011.
|
|||||
TMPY-00936 | TNF alpha Protein, Human, Recombinant | Human | E. coli | ||
TNF alpha Protein, Human, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 17.5 kDa and the accession number is P01375.
|
|||||
TMPY-04493 | BCMA/TNFRSF17 Protein, Human, Recombinant (rFc) | Human | HEK293 Cells | ||
BCMA/TNFRSF17 Protein, Human, Recombinant (rFc) is expressed in HEK293 mammalian cells with rFc tag. The predicted molecular weight is 33.3 kDa and the accession number is Q02223-1.
|
|||||
TMPY-01743 | 4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 18.8 kDa and the accession number is Q07011.
|
|||||
TMPY-05376 | 4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44 kDa and the accession number is Q07011.
|
|||||
TMPY-00072 | GITR/TNFRSF18 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
GITR/TNFRSF18 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 16 kDa and the accession number is Q9Y5U5-3.
|
|||||
TMPY-02667 | TROP-2 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
TROP-2 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 29.4 kDa and the accession number is Q8BGV3.
|
|||||
TMPY-00033 | 4-1BB Ligand/TNFSF9 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
4-1BB Ligand/TNFSF9 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 47.9 kDa and the accession number is A0A0U5J8I0.
|
|||||
TMPY-02726 | RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
RANKL/TNFSF11/CD254 Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 56 kDa and the accession number is AAC40113.1.
|
|||||
TMPJ-01466 | Osteoprotegerin Protein, Human, Recombinant (aa 22-401, His) | Human | HEK293 Cells | ||
TNFRSF11B is a secreted protein, containing 2 death domains and 4 TNFR-Cys repeats. TNFRSF11B is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL, TNFRSF11B inhibits nuclear kappa B (NF-κB) which is a central and rapid acting transcription factor for immune-related genes, and a key regulator of inflammation, innate immunity, and cell survival and differentiation. TNFRSF11B levels are influenced by voltage-dependent calcium channelsCav1.2. TNFRSF11B can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors (osteoclasts are related to monocytes/macrophages and are derived from granulocyte/macrophage-forming colony units (CFU-GM)) into osteoclasts and also regulates the resorption of osteoclasts in vitroand in vivo. TNFRSF11B binding to RANKL on osteoblast/stromal cells, blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast.
|
|||||
TMPY-01750 | HVEM Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
HVEM Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 19 kDa and the accession number is A0A024R052.
|
|||||
TMPY-01423 | OX40/TNFRSF4 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
OX40/TNFRSF4 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 21.7 kDa and the accession number is P43489.
|
|||||
TMPY-01294 | TNF alpha Protein, Mouse, Recombinant | Mouse | E. coli | ||
TNF alpha Protein, Mouse, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 17.39 kDa and the accession number is P06804.
|
|||||
TMPJ-00994 | LTBR Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
It is a single-pass type I membrane protein and contains 4 TNFR-Cys repeats. The protein is a member of the tumor necrosis factor (TNF) family of receptors. It is expressed on the surface of most cell types, including cells of epithelial and myeloid lineages, but not on T and B lymphocytes. The protein is the receptor for the heterotrimeric lymphotoxin containing LTA and LTB, and for TNFS14/LIGHT. It promotes apoptosis via TRAF3 and TRAF5 and may play a role in the development of lymphoid organs. The encoded protein and its ligand play a role in the development and organization of lymphoid tissue and transformed cells. Activation of the encoded protein can trigger apoptosis. Not only does the TNFRSF3 help trigger apoptosis, it can lead to the release of the cytokine interleukin 8. Overexpression of TNFRSF3 in Human Cells cells increases IL-8 promoter activity and leads to IL-8 release. TNFRSF3 is also essential for development and organization of the secondary lymphoid organs and chemokine release.
|
|||||
TMPY-04832 | OX40L/TNFSF4 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
OX40L/TNFSF4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 46.6 kDa.
|
|||||
TMPY-02096 | TACI Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TACI Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 14.8 kDa and the accession number is O14836-2.
|
|||||
TMPH-02975 | Wilms tumor protein homolog Protein, Mouse, Recombinant (His & Myc) | Mouse | E. coli | ||
Wilms tumor protein homolog Protein, Mouse, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 56.7 kDa and the accession number is P22561.
|
|||||
TMPY-05767 | 4-1BB/CD137/TNFRSF9 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
4-1BB/CD137/TNFRSF9 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 19.00 kDa and the accession number is P20334.
|
|||||
TMPY-04722 | DcR1/TRAILR3 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TNFRSF10C CNV in patients with CRC is associated with distant metastatic disease. A high frequency of CGI methylation in the TNFRSF10C promoter results in inactivation of the gene and enhancement of tumor growth in most PC cell lines (except CFPAC-1). Inactivation of TNFRSF10C by CpG island (CGI) hypermethylation can play an important role in PC progression and be potentially useful as a diagnostic marker and a new therapeutic approach for PC.
|
|||||
TMPY-01262 | TROP-2 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TROP-2 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 29.4 kDa and the accession number is P09758.
|
|||||
TMPY-03364 | RANKL/TNFSF11/CD254 Protein, Human, Recombinant | Human | HEK293 Cells | ||
RANKL/TNFSF11/CD254 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 20.5 kDa and the accession number is AAC51762.1.
|
|||||
TMPY-03674 | RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) | Human | HEK293 Cells | ||
RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag. The predicted molecular weight is 52.4 kDa and the accession number is AAC51762.1.
|
|||||
TMPH-02312 | Wilms tumor protein/WT1 Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Transcription factor that plays an important role in cellular development and cell survival. Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'. Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors. Isoforms containing the KTS motif may bind mRNA and play a role in mRNA metabolism or splicing. Isoform 1 has lower affinity for DNA, and can bind RNA.
|
|||||
TMPY-04142 | RANK/TNFRSF11A Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
RANK/TNFRSF11A Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 46.8 kDa and the accession number is Q9Y6Q6-3.
|
|||||
TMPY-01920 | BAFF/TNFSF13B Protein, Human, Recombinant (HEK293) | Human | HEK293 Cells | ||
BAFF/TNFSF13B Protein, Human, Recombinant (HEK293) is expressed in HEK293 mammalian cells. The predicted molecular weight is 17 kDa and the accession number is Q9Y275-1.
|
|||||
TMPY-05365 | BAFF/TNFSF13B Protein, Human, Recombinant (Avi & Fc), Biotinylated | Human | HEK293 Cells | ||
BAFF/TNFSF13B Protein, Human, Recombinant (Avi & Fc), Biotinylated is expressed in HEK293 mammalian cells with AVI and Fc tag. The predicted molecular weight is 45.6 kDa and the accession number is A0A0U5J7Q1.
|
|||||
TMPJ-00147 | FOLR1 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
FOLR1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with C-Fc tag. The predicted molecular weight is 55-75 kDa and the accession number is P15328.
|
|||||
TMPJ-00603 | TL1A/TNFSF15 Protein, Mouse, Recombinant | Mouse | E. coli | ||
Tumor Necrosis Factor Ligand Superfamily Member 15 (TNFSF15) is a new member of the tumor necrosis factor family. TNFSF15 is predominantly an endothelial cell-specific gene, and recombinant TNFSF15 is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. TNFSF15 exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli and programmed cell death of proliferating cells. These activities are highly specific to endothelial cells. TNFSF15 is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that TNFSF15 functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature.
|
|||||
TMPY-01166 | TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
TNFR2/CD120b/TNFR1B Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.6 kDa and the accession number is P20333-1.
|
|||||
TMPY-01185 | DR5/TRAIL R2 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
DR5/TRAIL R2 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 15.7 kDa and the accession number is O14763-1.
|
|||||
TMPJ-00280 | TNF R1 Protein, Mouse, Recombinant | Mouse | E. coli | ||
Tumor necrosis factor receptor superfamily member 1A (Tnfrsf1a) is a member of the tumor necrosis factor receptor superfamily. Tnfrsf1a is one of the major receptors for the tumor necrosis factor-alpha. It can activate the transcription factor NF-κB, mediate apoptosis, and function as a regulator of inflammation. Antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRADD and TRAF2 have been shown to interact with this receptor, and thus play regulatory roles in the signal transduction mediated by the receptor. Germline mutations of the extracellular domains of this receptor were found to be associated with the human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS) or periodic fever syndrome
|
|||||
TMPY-02228 | p53 Protein, Cynomolgus, Recombinant | Cynomolgus | E. coli | ||
p53, also known as Tp53, is a DNA-binding protein which belongs to the p53 family. It contains transcription activation, DNA-binding, and oligomerization domains. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 (TP53) is a transcription factor whose protein levels and post-translational modification state alter in response to cellular stress (such as DNA damage, hypoxia, spindle damage). Activation of p53 begins through a number of mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs. MDM2 is a ubiquitin ligase that binds p53 and targets p53 for proteasomal degradation. Phosphorylation, p14ARF and USP7 prevent MDM2-p53 interactions, leading to an increase in stable p53 tetramers in the cytoplasm. Further modifications such as methylation and acetylation lead to an increase in Tp53 binding to gene specific response elements. Tp53 regulates a large number of genes (>100 genes) that control a number of key tumor suppressing functions such as cell cycle arrest, DNA repair, senescence and apoptosis. Whilst the activation of p53 often leads to apoptosis, p53 inactivation facilitates tumor progression. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Defects in TP53 are a cause of esophageal cancer, Li-Fraumeni syndrome, lung cancer and adrenocortical carcinoma.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-02402 | WTAP Protein, Human, Recombinant (GST) | Human | E. coli | ||
Wilms' tumor 1-associating protein (WTAP) was previously identified as a protein associated with Wilms' tumor-1 (WT-1) protein that is essential for the development of the genitourinary system. WT1 was originally identified as a tumor suppressor for Wilms' tumor, but it is also overexpressed in a variety of cancer cells. The WTAP-WT1 axis in vascular cells suggest that WTAP is a vital and multifaceted regulator of vascular remodeling. WTAP has been suggested to function in alternative splicing, stabilization of mRNA, and cell growth. Knocking down endogenous WTAP increased Smooth muscle cells (SMCs) proliferation, because of increased DNA synthesis and G(1)/S phase transition, together with reduced apoptosis. These effects could be the result of WTAP suppressing the transcriptional activity of WT1 in SMCs. WTAP may thus also play a role in messenger RNA processing in mammalian cells, either dependent on or independent of its interaction with WT1.
|
|||||
TMPY-05152 | TROP-2 Protein, Rat, Recombinant (His) | Rat | HEK293 Cells | ||
TROP-2 Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 29.5 kDa and the accession number is A0A0G2JSJ1.
|